Home › Compare › TYGIF vs ABBV
TYGIF yields 0.72% · ABBV yields 3.06%● Live data
📍 TYGIF pulled ahead of the other in Year 7
Combined, TYGIF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TYGIF + ABBV for your $10,000?
Toyo Gosei Co.,Ltd. manufactures and sells photosensitive materials for photolithography primarily in Japan. The company offers photosensitive materials primarily for use in the microfabrication of semiconductor integrated circuits and liquid crystal displays, and manufacture of color filters; and a range of high-purity photo acid generators and resins that are used in chemical amplifiers. It is also involved in the recovery of waste solvents and volatile organic compounds through its distillation plants; marketing of various synthetic products; and the supply of electrolytes and ionic liquids used in electric double-layer capacitors. In addition, the company produces aroma chemicals for daily-use products, including shampoos and body soaps, as well as for the flavors of food products; and researches and develops, manufactures, and sells materials for batteries and electrical double layer capacitors. Further, it provides logistics services, such as receiving and shipping systems, storage facilities, and analysis equipment; photosensitive materials for use in the culturing of cells and protein enzymes; and warehousing and goods transportation services. The company was formerly known as Nihon Acetylene Chemical Engineering Co., Ltd. and changed its name to Toyo Gosei Co.,Ltd. in May 1961. Toyo Gosei Co.,Ltd. was founded in 1954 and is headquartered in Tokyo, Japan.
Full TYGIF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.